News
-
-
PRESS RELEASE
Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026
Formycon reports positive operational progress and strong revenue growth in the first quarter of 2026. Achievements in biosimilar portfolio and strategic roadmap. Financial figures and guidance confirmed -
-
PRESS RELEASE
Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences
Formycon AG invites to conference call on Q1 2026 results and announces participation in investor conferences. Key focus on biosimilars and financial outlook -
-
PRESS RELEASE
Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive® and Baiama® are now available in the European Union
Formycon expands commercial portfolio with the launch of Aflibercept biosimilars Ahzantive(R) and Baiama(R) in the European Union, reinforcing market penetration and growth strategy -
-
PRESS RELEASE
Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships
Formycon AG reports successful financial year 2025 with operational progress, market growth, and strategic partnerships. Forecast for 2026 includes revenue growth and positive EBITDA -
-
PRESS RELEASE
Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026
Formycon AG to hold Conference Call on Results of FY 2025 and participate in international Investor Conferences in Q2 2026. Details and registration at provided links
